Replies to post #122785 on Biotech Values

[DewDiligence]

Good point again. Approval of Xarelto for primary VTE prevention following hip/knee surgery is hardly a surprise for MNTA investors—or for anybody who has done a modicum of DD on the anticoagulant arena.